Race Oncology (ASX:RAC) has received human ethics approval to commence its HARNESS-1 Phase 1a/b clinical trial evaluating RC220, its next-generation formulation of bisantrene, in combination with AstraZeneca's TAGRISSO (osimertinib) for patients with EGFR-mutated non-small cell lung cancer.
Race Oncology secures human ethics approval for lung cancer trial of RC220
November 26, 2025 Australian Biotech
Latest Video
New Stories
-
Canberra discovers what it really feels like to face a single buyer, and the response is hypocrisy
November 17, 2026 - - Latest News -
US biotech lobby's call for a White House strategy echoes AusBiotech push
November 17, 2026 - - Latest News -
Third global honour of 2026 for cochlear implant pioneer Graeme Clark
November 17, 2026 - -
Ipsen marks 25 years in Australia as rare disease listings broaden patient access
November 17, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 -

